



For further information:  
Marta Campos Martínez  
[mcampos@rovi.es](mailto:mcampos@rovi.es)  
Tel: +34 91 244 44 22

## **ROVI exercises the Purchase Option held over the health register of Rhodogil® in Spain**

**Madrid – 6th of June, 2013** – Laboratorios Farmacéuticos Rovi (ROVI) and Sanofi have announced they have reached an agreement for ROVI to exercise the Purchase Option held over the health register of Rhodogil® in Spain, which was owned by Sanofi.

Under this agreement, Rhodogil® will be marketed by ROVI in Spain as soon as the administrative processes for the authorization of the transfer of the marketing authorization are completed before the Spanish Agency of Drugs and Health Products.

Since last 29th of July, 2003, ROVI have been providing to Sanofi commercial promotion services for Rhodogil® in Spain.

Rhodogil® is a synergistic combination of two antibacterial: metronidazole and spiramycin. Is effective against a broad spectrum of germs, especially those associated with infections of the oral cavity (e.g. dental infections).

According to IMS Health data, Rhodogil® sales in Spain reached 3.6 million Euros over the last twelve months to April 2013 (MAT April 2013), and in the case of macrolide antibiotics market and similar (such as Rhodogil®) reached a total 34.1 million Euros, reflecting the product a market share in units of 15% for that period.

Juan López-Belmonte Encina, Managing Director of ROVI, commented: "With Rhodogil®, ROVI expands its product portfolio providing to specialists in dental practices an effective alternative in the treatment of oral and dental infections, contributing, thus, to improve the quality of life of patients suffering from this ailment".

## **About ROVI**

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISMTM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: [www.rovi.es](http://www.rovi.es)

## **About SANOFI**

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).